Skip to content

With EACS release, all international HIV treatment guidelines agree on when to start – for the first time since 2006

Panel presenting the treatment guidelines at EACS 2015. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety

Bart Rijnders, presenting at EACS 2015. Photo by Liz Highleyman, hivandhepatitis.com

Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?

Pedro Cahn, presenting at EACS 2015. Photo by Liz Highleyman, hivandhepatitis.com

Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved

Jens Lundgren, presenting at EACS 2015. Photo by Liz Highleyman, hivandhepatitis.com

One third of people with HIV in US study are not virally suppressed on antiretroviral therapy

How do we treat the world? Experts discuss moving to universal HIV treatment

Studies continue to support tenofovir alafenamide combination pill as it nears US approval

At least 25,000 people in the US may now be using PrEP

HIV attachment inhibitor BMS-663068 matches atazanavir in phase 2b study